Literature DB >> 24959727

Evaluation of an improved sustained-release buprenorphine formulation for use in mice.

Jason R Healy1, Jennifer L Tonkin, Stacey R Kamarec, Mitchell A Saludes, Sherif Y Ibrahim, Rae R Matsumoto, Jeffrey H Wimsatt.   

Abstract

OBJECTIVE: To evaluate analgesic effects of an improved sustained-release buprenorphine (BUP-SR) formulation administered to mice. ANIMALS: 36 male Swiss-Webster mice. PROCEDURES: Mice were assigned to each of 3 treatment groups (n = 12 mice/group). Treatments were administered SC (vehicle [control treatment], 1.5 mg of buprenorphine hydrochloride [BUP-HCl]/kg, and 1.5 mg of BUP-SR/kg). Mice were evaluated (total activity, gastrointestinal tract motility, respiratory rate, cataleptic behavior, and tall-flick and hot plate nociception tests) to determine behavioral and physiologic responses at 4, 24, and 48 hours after treatment administration. Body weight and respiratory rate were measured before and at each time point after treatment administration.
RESULTS: SC administration of BUP-SR resulted in significant antinociception effects for 48 hours for the hot plate and tall-flick nociception tests without substantial adverse effects. Gastrointestinal tract motility and total activity were higher at 4 hours for mice receiving BUP-SR than for mice receiving the vehicle, but values were the same between these groups at 24 and 48 hours. The BUP-SR group had a lower respiratory rate than did the control group at all times after treatment administration. Mice treated with BUP-SR had no significant changes in body weight during the study, whereas mice treated with BUP-HCl had a significant decrease in body weight at 24 and 48 hours. CONCLUSIONS AND CLINICAL RELEVANCE: BUP-SR administration resulted in antinociception effects for 48 hours. Results of this study indicated that the improved BUP-SR formulation could be safely administered SC and conferred superior analgesia, compared with that for BUP-HCl, in mice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24959727     DOI: 10.2460/ajvr.75.7.619

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  17 in total

1.  Plasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.

Authors:  Chiara Zullian; Pablo Lema; Melissa Lavoie; Aurore Dodelet-Devillers; Francis Beaudry; Pascal Vachon
Journal:  Can J Vet Res       Date:  2016-07       Impact factor: 1.310

2.  Pharmacokinetics and Adverse Effects of 3 Sustained-release Buprenorphine Dosages in Healthy Guinea Pigs (Cavia porcellus).

Authors:  Andrea S Zanetti; Sumanth K Putta; Donald B Casebolt; Stan G Louie
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-11-01       Impact factor: 1.232

3.  Analgesic Efficacy of Subcutaneous-Oral Dosage of Tramadol after Surgery in C57BL/6J Mice.

Authors:  Rocio Evangelista-Vaz; Alessandra Bergadano; Margarete Arras; Paulin D Jirkof
Journal:  J Am Assoc Lab Anim Sci       Date:  2018-06-05       Impact factor: 1.232

4.  Pharmacokinetics and Paw Withdrawal Pressure in Female Guinea Pigs (Cavia porcellus) Treated with Sustained-Release Buprenorphine and Buprenorphine Hydrochloride.

Authors:  Brian J Smith; Daniel J Wegenast; Ryan J Hansen; Ann M Hess; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-11       Impact factor: 1.232

5.  Immunomodulation Associated with Sustained-release Buprenorphine in Female CD1 Mice Challenged with Ovalbumin.

Authors:  Alexis A Allen; Lon V Kendall
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-07-18       Impact factor: 1.232

6.  Serum Buprenorphine Concentrations and Behavioral Activity in Mice After a Single Subcutaneous Injection of Simbadol, Buprenorphine SR-LAB, or Standard Buprenorphine.

Authors:  Page H Myers; David R Goulding; Rebecca A Wiltshire; Christopher A McGee; Angela B Dickerson; Molly M Comins; Min Shi; Grace E Kissling; Fred B Lih; Leesa J Deterding; Kathy E Laber-Laird; Terry L Blankenship-Paris
Journal:  J Am Assoc Lab Anim Sci       Date:  2021-11-05       Impact factor: 1.232

7.  Effects of Standard and Sustained-release Buprenorphine on the Minimum Alveolar Concentration of Isoflurane in C57BL/6 Mice.

Authors:  Philip C LaTourette; Emily M David; Cholawat Pacharinsak; Katechan Jampachaisri; Jennifer C Smith; James O Marx
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-04-08       Impact factor: 1.232

8.  Efficacy of Sustained-Release Buprenorphine in an Experimental Laparotomy Model in Female Mice.

Authors:  Lon V Kendall; Daniel J Wegenast; Brian J Smith; Kathryn M Dorsey; Sooah Kang; Na Young Lee; Ann M Hess
Journal:  J Am Assoc Lab Anim Sci       Date:  2016-01       Impact factor: 1.232

9.  Clinical Management of Pain in Rodents.

Authors:  Patricia L Foley; Lon V Kendall; Patricia V Turner
Journal:  Comp Med       Date:  2019-12-10       Impact factor: 0.982

10.  Lipid bound extended release buprenorphine (high and low doses) and sustained release buprenorphine effectively attenuate post-operative hypersensitivity in an incisional pain model in mice (Mus musculus).

Authors:  Kaela Navarro; Katechan Jampachaisri; Monika Huss; Cholawat Pacharinsak
Journal:  Animal Model Exp Med       Date:  2021-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.